Orthonika Limited secured $871,276 in funding for its synthetic total knee replacement.
Here's what you should know.
1. A group of angel investors supplemented funding Orthokina received from a Biomedical Catalyst award and an Industrial Challenge award.
2. Orthonika will use the funding to accelerate the implant's biomechanical testing and to carry out a pre-clinical pilot trial.
3. Orthonika Co-Founder and CEO Mario Alberto Accardi, PhD, said in a release, "This investment demonstrates a strong endorsement of our progress in developing a novel solution for meniscus injury and allows us to cement our network of collaborators and suppliers."